FDA Requires Vision Loss Warning on Novo Nordisk and Eli Lilly GLP-1 Drugs
The US Food and Drug Administration (FDA) has mandated warning labels on GLP-1 receptor agonist drugs, including Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro, Zepbound, and Foundayo, due to a potential rare side effect called non-arteritic anterior ischemic optic neuropathy (NAION). This condition can cause sudden, painless vision loss and possibly permanent damage. Both companies are reviewing the FDA's update, with Novo Nordisk affirming the benefits of its drugs and Lilly evaluating the new information. The warning applies to all marketed GLP-1 drugs, reflecting reported cases across products.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 55/100.
Outlets measured: economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 9 Nov, 05:46 pm. Other outlets followed.